

Draft programme 28/11/2017



**Clinical Updates on
CLL and Indolent Lymphoma
Paris, France
2-4 March 2018**

Chairs: Christian Buske (Ulm), Catherine Wu (Boston), Pier Luigi Zinzani (Bologna)

Friday, March 2, 2018

13:55–14:00 Welcome

SESSION I GENOMIC LANDSCAPE OF CLL
Chair: Catherine Wu (Boston)

14:00-14:15 CLL pathogenesis: microenviromental and genetics Carlo M. Croce (Columbus)
14:15-14:20 *Discussion*

14:20-14:35 Genetic portrait of CLL Catherine Wu (Boston)
14:35-14:40 *Discussion*

14:40-14:55 Predictive biomarkers Davide Rossi (Bellinzona)
14:55-15:00 *Discussion*

15:00-15:45 *Panel discussion*
Moderator: Catherine Wu (Boston)
Discussants: Carlo M. Croce (Columbus)
Catherine Wu (Boston)
Davide Rossi (Bellinzona)

15:45-16:00 Coffee Break

SESSION II CHEMOIMMUNOTHERAPY IN CLL
Chair: Michael J. Keating (Houston)

16:00-16:20 FCR Michael J. Keating (Houston)
16:20-16:25 *Discussion*

16:25-16:45 BR Olivier Tournilhac
16:45-16:50 *Discussion* (Clermont-Ferrand)

16:50-17:10 Chlorambucil plus anti-CD20 MoAb Valentin Goede (Cologne)
17:10-17:15 *Discussion*

17:15-18:15 *Plenary Round Table: Is there a role for chemoimmunotherapy in the therapeutic scenario of CLL?*
Moderator: TBA
Discussants: Michael J. Keating (Houston)
Valentin Goede (Cologne)
Olivier Tournilhac (Clermont-Ferrand)

Saturday, March 3, 2018

SESSION III	NOVEL TARGETED THERAPIES IN CLL Chair: John Gribben (London)	
09:00-09:15	Ibrutinib	John Gribben (London)
09:15-09:20	<i>Discussion</i>	
09:20-09:35	Idelalisib	Andrew Zelenetz (New York)
09:35-09:40	<i>Discussion</i>	
09:40-09:55	Venetoclax	Peter Hillmen (Leeds)
09:55-10:00	<i>Discussion</i>	
10:00-11:00	<i>Plenary Round Tables:</i> - <i>Is it possible to stop treatment with the new targeted therapies?</i> - <i>Are there advances with combinations of therapies using targeted agents?</i> - <i>Which is the best sequence of these novel therapies?</i> <i>Moderator: Peter Hillmen (Leeds)</i> <i>Discussants: John Gribben (London)</i> <i>Andrew Zelenetz (New York)</i> <i>Peter Hillmen (Leeds)</i>	
11:00-11:20	<i>Coffee Break</i>	
SESSION IV	BIOLOGY OF FOLLICULAR LYMPHOMA Chair: Stefano Pileri (Bologna)	
11:20-11:35	Histology	Stefano Pileri (Bologna)
11:35-11:40	<i>Discussion</i>	
11:40-11:55	Biology	Hans-Guido Wendel (New York)
11:55-12:00	<i>Discussion</i>	
12:00-12:15	From genetics to pathogenesis	Riccardo Dalla-Favera
12:15-12:20	<i>Discussion</i>	(New York)
12:20-13:00	<i>Plenary Round Table: New potential targets and biomarkers</i> <i>Moderator: Riccardo Dalla-Favera (New York)</i> <i>Discussants: Stefano Pileri (Bologna)</i> <i>Hans-Guido Wendel (New York)</i> <i>Riccardo Dalla-Favera (New York)</i>	
13:00-14:00	<i>Lunch</i>	
SESSION V	BIOLOGY AND PROGNOSTIFICATION OF FL Chair: Pier Luigi Zinzani (Bologna)	
14:00-14:15	Update WHO	Stefano Pileri (Bologna)
14:15-14:20	<i>Discussion</i>	
14:20-14:35	Clonal evolution	Michael R. Green (Houston)
14:35-14:40	<i>Discussion</i>	

14:40-14:55 14:55-15:00	Prognostification <i>Discussion</i>	Oliver Weigert (Munich)
SESSION VI TREATMENT OF FOLLICULAR LYMPHOMA Chair: Christian Buske (Ulm)		
15:00-15:15 15:15-15:20	Early stage patient, first line <i>Discussion</i>	Eva Kimby (Stockholm)
15:20-15:35 15:35-15:40	Advanced stage patient, first line <i>Discussion</i>	Christian Buske (Ulm)
15:40-15:55 15:55-16:00	Salvage therapy <i>Discussion</i>	Vincent Ribrag (Villejuif)
16:00-16:20	<i>Coffee Break</i>	
16:20-16:35 16:35-16:40	Transformed follicular lymphoma <i>Discussion</i>	TBA
16:40-16:55 16:55-17:00	New agents <i>Discussion</i>	Gilles Salles (Lyon)
17:00-17:40	<i>Plenary Round Table: Future standards in follicular lymphoma</i> Moderator: TBA Discussants: Eva Kimby (Stockholm) Christian Buske (Ulm) Vincent Ribrag (Villejuif) TBA Gilles Salles (Lyon) Pier Luigi Zinzani (Bologna)	

Sunday, March 4, 2018

SESSION VII PATHOBIOLOGY AND THERAPY OF MARGINAL ZONE LYMPHOMA Chairs: German Ott (Suttgart) & Pier Zinzani (Bologna)		
08:30-08:45 08:45-08:50	Histology <i>Discussion</i>	German Ott (Suttgart)
08:50-09:05 09:05-09:10	Biology and molecular genomics <i>Discussion</i>	Ming-Qing Du (Cambridge)
09:10-09:25 09:25-09:30	Prognostic models <i>Discussion</i>	Carlos Montalban (Madrid)
09:30-09:45 09:45-09:50	Clinical aspects <i>Discussion</i>	Catherine Thieblemont (Paris)
09:50-10:10	<i>Coffee Break</i>	
10:10-10:25 10:25-10:30	Treatment of splenic marginal zone lymphoma <i>Discussion</i>	Markus Raderer (Vienna)

10:30-10:45	Treatment of nodal marginal zone lymphoma	Catherine Thieblemont (Paris)
10:45-10:50	<i>Discussion</i>	
10:50-11:05	Treatment of MALT lymphomas	Emanuele Zucca (Bellinzona)
11:05-11:10	<i>Discussion</i>	
11:10-11:50	<i>Plenary Round Table: Future standard treatments for MZL</i> <i>Moderator: Pier Luigi Zinzani (Bologna)</i> <i>Discussants: Carlos Montalban (Madrid)</i> <i>Catherine Thieblemont (Paris)</i> <i>Markus Raderer (Vienna)</i> <i>Emanuele Zucca (Bellinzona)</i>	
11:50-12:00	<i>Round up of meeting</i>	

MEETING CLOSURE